Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

Abstract

After 2 years of follow-up and stringent discontinuation of DAPT beyond 12 months, Resolute ZES and Xience V EES showed similar results in terms of safety and efficacy for treating patients with a majority of complex lesions and off-label indications for drug-eluting stents. (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente [TWENTE]; NCT01066650).

Zotarolimus compared with everolimus eluting stents‐angiographic and clinical results after recanalization of true coronary chronic total occlusions

“…In the randomized HOST ASSURE trial including 3755 all-comers patients comparing the EES and the ZES, TLF was 2.9% after one year in both arms (P ¼ 0.98) [16]. In the TWENTE trial 1391 patients were randomly treated with EES or ZES [17]. After 2 years the EES showed a significantly lower rate of target lesion revascularization (2.6 vs. 4.9%, P ¼ 0.03).…”

Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents

“…All trials randomized the participants, and reported details of the randomization process used [6,7,[12][13][14]. All studies used methods of concealed treatment allocation adequately, except one [7].…”

“…Five published trials [6,7,[12][13][14] with a total of 9853 patients were included in our study. The number of patients in each study ranged from 650 to 3755 and the duration of follow-up varied from 12 to 48 months (mean duration, 21.6 months).…”

“…Five trials [6,7,[12][13][14] provided long-term follow-up data on ARC definite and/or probable ST. There were 5552 patients in the EES group, and ST occurred in 47 patients (0.85%).…”

“…Evidence from a comprehensive network metaanalysis showed that compared with BMS and firstgeneration DES, EES was associated with better stent endothelialization [3], which is strongly linked to a reduced rate of late and very late ST [3][4][5]. However, the TWENTE trial showed that 2-year rates of definite or probable ST were comparable (1.2 vs. 1.4%, P = 0.63) between the EES and ZES groups [6]. Moreover, the 4-year rates of late ST (0.2 vs. 0.6%, P = 0.10) and very late ST (0.7 vs. 0.9%, P = 0.81) were also similar between the two groups in the RESOLUTE study [7].…”